camptothecin has been researched along with Follicular Thyroid Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Btaouri, HE; Dedieu, S; Langlois, B; Martiny, L; Morjani, H; Rath, G; Sartelet, H; Schneider, C | 1 |
1 other study(ies) available for camptothecin and Follicular Thyroid Carcinoma
| Article | Year |
|---|---|
De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Ceramides; Doxorubicin; Humans; Oxidoreductases; Thyroid Neoplasms; Tumor Cells, Cultured | 2009 |